Retension Pharmaceuticals (NASDAQ:RTSN) Stock Rated “Buy” in New Coverage at Guggenheim

Analysts at Guggenheim assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research report issued on Monday, Benzinga reports. The firm set a “buy” rating and a $55.00 price target on the stock. Guggenheim‘s target price indicates a potential upside of 384.15% from the company’s current price.

Retension Pharmaceuticals Stock Performance

Shares of NASDAQ RTSN opened at $11.36 on Monday. Retension Pharmaceuticals has a 1 year low of $9.66 and a 1 year high of $18.64.

Insider Buying and Selling at Retension Pharmaceuticals

In related news, CEO Eric Keller bought 20,800 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were bought at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares in the company, valued at $5,080,524. This trade represents a 5.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Franklin Berger bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average cost of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $120,000. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.